Navigation Links
Medrio, a Leading EDC and eClinical SaaS Provider for Clinical Research, Announces the Highly Anticipated Release of Medrio 8.1 with iPad Support
Date:4/23/2013

San Francisco, CA (PRWEB) April 23, 2013

Medrio, a leading EDC and eClinical SaaS provider for clinical research, announces the highly anticipated release of Medrio 8.1 with iPad support. In this release, the same powerful platform has been redesigned with a fresh new look and offers customers enhanced navigation for ease of use.

Highlights of the Medrio 8.1 with iPad support release:

  •         Most commonly used functions are more readily available
  •         New workflow-driven home screen with high-level summaries
  •         Enter and monitor data on-site with your iPad
  •         Manage your study remotely

“The new 8.1 Medrio user interface was thoughtfully designed and helps the user navigate the pages more intuitively,” said Ashleigh Wilson, Clinical Data Manager at Heartflow. “It allows me to find what I need with fewer clicks and less time spent scrolling. The addition of iPad support will help our monitors greatly in the field.”

“We are thrilled to unveil Medrio 8.1, a more user-friendly platform we’ve designed in order to make our system simpler to navigate and perform the tasks necessary to conduct clinical trials,” said Jeff Johnson, Medrio’s Director of Customer Experience. “We’ve also incorporated features to improve system performance and maintain our high level of reliability. This has been a collaborative effort and our customers are responding with a great deal of excitement about the new platform and superior usability.”

About Medrio, Inc.

Medrio offers an integrated eClinical Software as a Service (SaaS) platform with a fully hosted Electronic Data Capture (EDC) system that drastically reduces study timelines and costs by putting study managers in control of their studies. By enabling studies to be built completely online without the need for any custom development, Medrio eClinical software allows studies to be ready in days instead of weeks. Medrio has been used successfully in Phase I-IV trials, registries, and other clinical studies by a number of leading contract research organizations (CROs), as well as biopharmaceutical and device companies. Founded in 2005, Medrio is headquartered in the San Francisco Bay Area. For more information visit http://www.medrio.com.

Read the full story at http://www.prweb.com/releases/2013/4/prweb10525701.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Life Technologies Acquires KDR Biotech Co., LTD., Leading Reagents Distributor
2. Antimicrobial Test Laboratories Emerges as Leading Provider of Virus Testing Services
3. Biotrial, a Successful Leading CRO, Continues to Expand its Activities, Creating a Unique Neuroscience Pool of Talent and Capabilities: Biotrial Neuroscience
4. Leading Biotoxin & Mold Illness Authority Creates Certification Process for Treatment Protocol
5. Leading Chemical Manufacturer Expands Biobased Offering through Unique Distribution of Proven Green Spill Absorbent
6. Leading Photonics and Laser Researchers to Present Latest Work at SPIE Optics + Optoelectronics
7. Smith & Nephew hosts thought-leading surgeons, showcases new technology at American Academy of Orthopaedic Surgeons annual meeting
8. BioElectronics Product Cited for "Most Innovative New OTC Product" From Leading UK-based Healthcare Marketing Publication
9. Dr. Ali S. Faqi and Leading Scientists Author Ground-Breaking Toxicology Book from Elsevier
10. Alexandria Real Estate Equities, Inc. Announces Long-Term Lease with Leading Global Commercial-Stage Oncology Company, Onyx Pharmaceuticals, Inc., for New Build-to-Suit Facility in South San Francisco, California
11. Mylan to Acquire Agila to Create Leading Global Injectables Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... Prairie, WI (PRWEB) , ... June 23, 2016 ... ... consultancy focused on quality, regulatory and technical consulting, provides a free webinar ... is presented on July 13, 2016 at 12pm CT at no charge. , ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 ... a product subsidiary of Infosys (NYSE: ... to integrate the Onegini mobile security platform with ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration will ... to access and transact across channels. Using this ...
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
Breaking Biology News(10 mins):